

Home dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference



OPEN

Jeffrey Perl¹, Edwina A. Brown², Christopher T. Chan³, Cécile Couchoud⁴, Simon J. Davies⁵, Rümeyza Kazancıoğlu⁶, Scott Klarenbach⁷, Adrian Liew⁸, Daniel E. Weiner⁹, Michael Cheung¹⁰, Michel Jadoul¹¹, Wolfgang C. Winkelmayer¹² and Martin E. Wilkie¹³; for Conference Participants¹⁴

¹Division of Nephrology, St. Michael's Hospital and the Keenan Research Center in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; ²Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom; ³University Health Network, University of Toronto, Toronto, Ontario, Canada; ⁴REIN Registry, Agence de La Biomedicine, Paris, France; ⁵School of Medicine, Keele University, Staffordshire, United Kingdom; ⁶Department of Nephrology, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey; ⁷Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; ⁸The Kidney & Transplant Practice, Mount Elizabeth Novena Hospital, Singapore, Singapore; ⁹William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA; ¹⁰KDIGO, Brussels, Belgium; ¹¹Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium; ¹²Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; and ¹³Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

Home dialysis modalities (home hemodialysis [HD] and peritoneal dialysis [PD]) are associated with greater patient autonomy and treatment satisfaction compared with in-center modalities, yet the level of home-dialysis use worldwide is low. Reasons for limited utilization are context-dependent, informed by local resources, dialysis costs, access to healthcare, health system policies, provider bias or preferences, cultural beliefs, individual lifestyle concerns, potential care-partner time, and financial burdens. In May 2021, KDIGO (Kidney Disease: Improving Global Outcomes) convened a controversies conference on home dialysis, focusing on how modality choice and distribution are determined and strategies to expand home-dialysis use. Participants recognized that expanding use of home dialysis within a given health system requires alignment of policy, fiscal resources, organizational structure, provider incentives, and accountability. Clinical outcomes across all dialysis modalities are largely similar, but for specific clinical measures, one modality may have advantages over another. Therefore, choice among available modalities is preference-sensitive, with consideration of quality of life, life goals, clinical characteristics, family or care-partner support, and living environment. Ideally, individuals, their care-partners, and their healthcare teams will employ shared decision-making in assessing initial and subsequent kidney failure treatment options. To meet this goal, iterative, high-quality

education and support for healthcare professionals, patients, and care-partners are priorities. Everyone who faces dialysis should have access to home therapy. Facilitating universal access to home dialysis and expanding utilization requires alignment of policy considerations and resources at the dialysis-center level, with clear leadership from informed and motivated clinical teams.

Kidney International (2023) **103**, 842–858; <https://doi.org/10.1016/j.kint.2023.01.006>

KEYWORDS: dialysis modality; healthcare policy; hemodialysis; home dialysis; peritoneal dialysis; quality of life

Copyright © 2023, KDIGO: Kidney Disease Improving Global Outcomes. Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Home dialysis modalities, including home hemodialysis (HD) and peritoneal dialysis (PD), are associated with increased patient autonomy and treatment satisfaction and are sometimes less costly than in-center HD (ICHD).^{1–7} Yet, despite mounting evidence regarding the benefits of home dialysis, its use worldwide remains low. The availability and use of home-based dialysis therapies remain variable, shaped by a complex interplay among national healthcare policies, systems for dialysis delivery, financial considerations, and culture. In many regions, including several high-income areas, individuals facing kidney failure have limited or no access to home HD. For PD, recent substantial growth in use among low- and middle-income regions has been accompanied by a concomitant decline in PD among many high-income regions.⁸

Globally, the net burden of untreated kidney disease is rising.⁹ The population of individuals receiving dialysis therapy is projected to double from 2010 to 2030.¹⁰ In response, increasing worldwide home dialysis utilization may be a means

Correspondence: Jeffrey Perl, Division of Nephrology, St. Michael's Hospital, 61 Queen Street East, 9-128, Toronto ON M5C 2T2, Canada. E-mail: jeff.perl@utoronto.ca; or Martin E. Wilkie, Sheffield Kidney Institute, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK. E-mail: wilkieme@gmail.com

¹⁴Other Conference Participants are listed in the [Appendix](#).

Received 29 July 2022; revised 9 December 2022; accepted 9 January 2023; published online 31 January 2023

to improve universal access to kidney replacement therapy (KRT) in low- and middle-income regions by developing and implementing low-cost, self-managed dialysis.

In 2018, the first Kidney Disease: Improving Global Outcomes (KDIGO) dialysis controversies conference, entitled Dialysis Initiation, Modality Choice, Access, and Prescription, cemented the understanding that choice of dialysis modality plays a central role in a person-centered and goal-directed approach to KRT.¹¹ In 2019, the second KDIGO dialysis controversies conference addressed Blood Pressure and Volume Management in Dialysis, both of which are significantly and variably impacted by dialysis modality.¹² This third meeting of the KDIGO dialysis conference series focused on policy, facility, and patient factors affecting home dialysis utilization (Figure 1; Table 1), as well as considerations for expanding its use (Table 2).¹³

POLICY FACTORS AFFECTING MODALITY AVAILABILITY

Who pays for dialysis varies internationally and has significant implications for availability of care. Publicly funded treatment is free for patients in some regions, but in other regions,

individuals must pay for some or all services.¹⁴ Some models are hybrids in which modality access and coverage are influenced by whether the payer is public or private. For healthcare systems, providing access to dialysis and optimizing healthcare economics are often competing interests (Figure 2). The amount spent on healthcare is increasing annually for all Organisation for Economic Co-operation and Development nations.¹⁵ Dialysis care is expensive, and for many, it is associated with poor quality of life.^{16,17} For lower- and middle-income regions, costs of dialysis care are often too high to provide KRT to all patients with kidney failure.¹⁸ A rationale for PD-first policies in publicly funded systems is that the lowered costs maximize dialysis availability to the largest possible population¹⁹; however, a consequence of PD-first policies may be constraint of individual choice of therapy.²⁰

In addition to the considerable costs of dialysis therapy, its environmental impact is significant, and mitigation strategies should be prioritized.²¹ Action is required on waste reduction, as well as efficient energy and water use, which apply equally to home- and center-based dialysis. A clear advantage of home therapies is the lower level of need for transportation and the decreased associated carbon footprint; however, more-frequent




Figure 1 | Factors leading to either center-based or home-based dialysis. CKD, chronic kidney disease; PD, peritoneal dialysis.

Table 1 | Summary of consensus points and residual controversies

Consensus points
• All individuals in need of maintenance dialysis should have home dialysis as a potential treatment option • Economic and local policies have a strong role in dialysis modality distribution within a region • Clinical outcomes are comparable among existing dialysis modalities, although patient quality of life may be better with home dialysis across certain domains • Individualized care, patient choice, education, and shared decision-making are central to modality selection in environments where multiple dialysis treatment options are available • The choice of dialysis modality should be directed by the anticipated benefits to quality of life as perceived by the patient and care-partners • High-quality education and clinical experience for healthcare professionals around home dialysis therapies are priorities
Residual controversies and questions
• Is a stronger evidence base needed to support interventions purported to increase the use of home dialysis? • Is it advisable or feasible to initiate further randomized clinical trials of dialysis modality comparisons given prior efforts and the importance of patient choice? • How do we measure the success of home dialysis growth as use expands to individuals previously considered ineligible? • In what contexts or circumstances could PD-first policies be considered and endorsed? • How do we measure and cross-compare home dialysis utilization in the context of differential rates of transplantation and conservative nondialytic care?

PD, peritoneal dialysis.

dialysis in the home and the need to transport and deliver large volumes of solutions to the home can offset this benefit.²¹

Whether home dialysis can result in cost savings from the perspective of the payer is context-dependent. In general, PD costs are lower than ICHD costs, but this tends to be truer in high-income regions, largely due to staffing costs. In several countries, the cost of PD is greater than that of ICHD, often because of the high costs of consumables.²² Large-scale use of PD can lead to cost reductions, and local manufacturing of PD fluid reduces shipping and tariffs.

Modifying the frequency or amount of assistance with home dialysis also influences costs. Having trained personnel provide assistance to PD patients in their homes increases expense and may reduce realized cost savings relative to ICHD. For home HD, the first year of treatment has high costs associated with installation of equipment and initial patient training, but in subsequent years, costs become lower than those with ICHD.²² For patients who do not continue long enough on home HD to recoup training and set-up costs, savings may not be realized. High rates of transition, such as for kidney transplantation or a transition to ICHD, may increase costs of home, relative to center-based, therapies.²³

Regardless of region, home dialysis often results in at least some cost burden being shifted to patients or their care-partners. To offset these costs, some countries, including Canada, Australia, the United Kingdom, and New Zealand, have local reimbursement policies to individuals for power, water, and waste disposal. Whether such reimbursements influence choice of modality is unclear.

Expansion of use of home dialysis within a given healthcare system is complex and requires alignment of policy, fiscal resources, organizational structure, and provider incentives or accountability (Table 3). Financial and policy levers for influencing the use of home dialysis need to be contextualized to the population of interest, existing culture, healthcare infrastructure and resources, and health priorities and challenges. Policy makers, health economists, clinicians, patients, and their care-

partners all have varying priorities that need to be balanced. The most appropriate financial model and healthcare policy toward home dialysis should be determined by each jurisdiction, after considering the accessibility to dialysis, healthcare economics, sustainability, and local outcomes.

Historically, many successful PD initiatives have been operationalized at the payer and dialysis-provider level. Figure 3 documents countries in which high utilization of home dialysis can be attributed partly to such initiatives.^{24–29} In many regions, ICHD is the default and therefore predominant modality, and financial pressures to keep all stations in HD centers full may be present. In reimbursement models, the 4 key stakeholders are the payer, the dialysis provider, the nephrologist, and the patient (Figure 4). Actions by the payer and provider are likely to have the greatest impact. Payer interventions can take several forms, such as direct fiscal incentives or penalties, coverage for a particular modality type(s), capacity limits, or a combination of these. Incentives to providers should reach the team of professionals supporting home dialysis, including nurses, surgeons, and radiologists.³⁰ However, financial incentives alone are unlikely to increase use of home dialysis, as they are only one piece in a complex system.^{31,32}

EVALUATING AND COMPARING MODALITY OUTCOMES

Comparisons of clinical outcomes between home and ICHD are largely limited to observational studies, and the results can be challenging to interpret in the context of selection bias and confounding. Very few studies include robust measures of residual kidney function, frailty, or social determinants of health, limiting analysis of key subgroups. Most studies are from higher-income regions, limiting their global applicability.

Clinical outcomes

Peritoneal dialysis versus in-center hemodialysis. Although the evidence has major limitations, it suggests that age,^{33–38} gender,^{37,39,40} race,^{37,41,42} region, diabetes status, vascular access type,⁴³ and body mass index⁴³ affect relative survival

Table 2 | Research priorities for home dialysis outcomes and implementation

Standardized reporting and outcomes
- Define and identify core outcomes of critical importance and relevance to all home dialysis stakeholders - Use metrics to evaluate, report, and benchmark performance of dialysis modalities - Develop and test strategies for capturing, reporting, and disseminating key outcomes (e.g., worksheets, toolkits, scorecards)
Policy and economics
- Evaluate the role of setting regional targets for home dialysis utilization on usage rates - In regions with limited dialysis availability, explore the role of home dialysis and its delivery as a sustainable, low-cost approach - Develop policies that enable and improve access to technological innovation for home dialysis - Examine initiatives that reduce the ecological impact of dialysis - Evaluate and compare implementation of health economic models for dialysis delivery and their impact on home dialysis use - Evaluate whether the outcomes of PD-first policies are modified by differing local and regional circumstances - Evaluate whether physician reimbursement impacts rates of home dialysis utilization - Evaluate the cost-effectiveness of different models of assisted home dialysis
Facility and organizational culture
- Develop and test mechanisms that build a culture of confidence around home therapies for healthcare professionals, patients, and care-partners - Understand the optimal approaches to share expertise among networked facilities - Develop and test tools that assess and address physician and healthcare team bias in modality selection - Develop and test tools to assess home dialysis unit organizational culture
Modality education and decision-making
- Evaluate approaches to enhance shared decision-making and assess and measure shared decision-making uptake and effectiveness - Develop unbiased, commercial-free educational programs for staff, patients, care-partners, and family members - Evaluate and compare models of training, including the following: virtual and personalized training; online education (providers and patients); hybrid individual training and group training; remote and home training; integrated in-center and teaching-specific facilities that focus on self-care dialysis skills; transitional care facilities and standard dialysis facilities; and subspecialty home dialysis facilities and mixed facilities - Measure the impact of patient motivation and ability, for example, using patient activation measures and their role in home dialysis utilization - Use virtual platforms and leverage existing technology to develop novel methods (i.e., simulations) for education and training (especially for self-cannulation) - Evaluate best models for peer support (live and video) and assess their impact on patient-reported outcomes and home dialysis utilization
Technology, monitoring, and support
- Evaluate effectiveness of eHealth interventions and their integration into home management - Enhance communication and cooperation between dialysis providers and primary care providers - Evaluate the role of telehealth, remote monitoring, and virtual patient encounters on home dialysis utilization - Assess the prevalence of care-partner burnout and how it impacts home dialysis utilization and outcomes
Modality transition
- Analyze data from population-based registries on transitions between dialysis modalities and identify areas for improvement - Analyze perspectives of patients, care-partners, and health professionals on the process of modality transitions - Identify factors impacting the switching from in-center to home HD/PD and predictive factors of switching among home modalities - Map the recruitment pathway to facilitate home-to-home transition; and identify optimal transition pathways - Assess outcomes of patients who switch modalities, moving from in-center to home dialysis or among home modalities; map the recruitment pathway to facilitate this transition; and identify optimal transition pathways from PD to home HD
Assisted home dialysis
- Standardize definitions and data collection (clinical and economic) on assisted home dialysis - Initiate cost-effectiveness analyses of assisted home dialysis compared to unassisted home dialysis across a broad range of models of care delivery and regions - Compare paid versus unpaid assistance and type of assistance (professional vs. family) - Design studies inclusive of patient-centered outcomes and family-member outcomes (burden of care, physical and emotional fatigue, etc.) and consider comparator groups of nondialytic conservative care and alternate dialysis modalities

HD, hemodialysis; PD, peritoneal dialysis.

with PD or ICHD. Two prospective randomized controlled trials explored whether outcomes for those starting ICHD differ from outcomes for those starting PD. The first study ended prematurely, due to low enrollment,⁴⁴ and the second study had a substantial number of patients who declined randomization to modality.⁴⁵ These studies underscore the important role of patient choice in dialysis modality selection and illustrate logistical challenges that limit feasibility of controlled trials to compare home versus in-center dialysis.⁴⁵

Hemodialysis at home versus in-center. Several observational studies have compared home HD with ICHD. Although interpretation of these studies needs to be taken in the context of the various home HD prescriptions evaluated, findings have generally suggested that home HD is associated with lower rates of hospitalization, decreased mortality, and fewer adverse non-access events.^{46–51} Limited randomized controlled trial data suggest that intensive HD improves blood pressure control, regresses left ventricular hypertrophy, and normalizes phosphate




Figure 2 | Global perspectives on access to home-based dialysis. KRT, kidney replacement therapy.

levels without dietary restrictions, but adverse vascular access events may be increased.^{4,52} Given inherent biases in observational data and limited published subgroup data, what is still unclear is whether clinically important outcomes differ by modality, and, if so, which populations are most likely to derive substantial benefits from home dialysis versus ICHD.

Quality of life

Peritoneal dialysis versus in-center dialysis. Health-related quality of life is highly valued by patients and their families. Data from randomized controlled trials and observational studies^{53–55} comparing PD with ICHD have found only small differences in health-related quality of life by modality, with a marginally better physical component score among PD patients.^{7,53} In categorical analyses, 23% to 39% of ICHD patients, and 14% to 24% of PD patients, had the highest burden range (burden score <25), and 8% to 25% of ICHD patients, and 10% to 37% of PD patients, had the lowest reported burden.¹³ A study from the United Kingdom of frail, older patients highlighted similar quality of life with assisted PD and ICHD,^{54–56} although, an important finding is that older patients report being more satisfied with PD.^{54,57}

Table 3 | Factors required for expanding use of home dialysis within a healthcare system

• Healthcare policy (e.g., home dialysis-preferred or home dialysis-first policies) • Fiscal resources • Provider incentives and accountability • Measurement of impact and ongoing feedback

Quality and performance metrics for evaluating home dialysis programs

As home dialysis programs expand, identification of the most-appropriate metrics to use for assessing and enabling improvement of care is key. Data from the Standardized Outcomes in Nephrology (SONG) initiative indicate that life participation and fatigue are 2 key patient concerns in the dialysis community,^{58,59} yet these outcomes are challenging to measure and are therefore infrequently incorporated into quality-assessment programs. Additionally, very few of the quality practice indicators used to assess dialysis practice, such as vascular access type, blood stream infections, and calcium and phosphorus levels, directly address home dialysis. Others, including measures of small solute clearance (e.g., Kt/V), have limited evidence to support their use in individuals on home dialysis and, when implemented, may disadvantage facilities in quality-assessment programs.⁶⁰

Although efforts are in progress,⁶¹ standardization of metrics across countries or regions is lacking. A home-dialysis-specific (home HD and PD) patient experience measure has been developed for use in the US,⁶² although comparison of PROMs (patient-reported outcome measures) and PREMs (patient-reported experience measures) among sites of care and among patients can be difficult.

Quality metrics need to be feasible to implement (not limited by economic status or healthcare setting), standardized to reduce heterogeneity nationally and internationally, and meaningful to all end-users (Table 4⁶³). Tools to define quality can include measures of structure, process, and outcomes, with the first 2 items serving as surrogates for the third.⁶⁴ Patient-,




Figure 3 | Representation of countries with high utilization of home-based dialysis in prevalent patients with kidney failure. Countries with high utilization of home dialysis have implemented home dialysis–first or –preferred policies. Home dialysis–first policies have largely centered around peritoneal dialysis (as in Hong Kong,²⁴ Thailand,²⁵ Mexico,²⁶ and Colombia²⁷), although in some countries, home dialysis–preferred policies have included home-based hemodialysis (as in Canada, Australia, New Zealand, and multiple Scandinavian countries). Home dialysis–preferred policies may be implemented regionally within a given country and vary by the degree of financial incentives. Data obtained from US Renal Data System 2020 Annual Data Report,²⁸ except for Thailand,²⁵ and Australia and New Zealand.²⁹




Figure 4 | Economic drivers influencing use of home-based dialysis.

Table 4 | Potential quality metrics in home dialysis

Quality metric	Challenges in applying as a quality metric	PD	Home HD
Patient survival	- Heavily dependent on comorbidities and frailty - Whether to classify and capture cause of death - Whether to include dialysis withdrawal as a death event - How to account for deaths after transition to center-based therapy (these may be premorbid events underestimating home dialysis-related mortality)	✓	✓
Technique survival	- Applicable to both PD and home HD though published reports are mostly limited to PD; better understanding and evaluation in home HD is needed - What constitutes technique survival? - Classify temporary transition (whether to include specific time intervals) and the particular value of death-censored technique survival - Work is underway to standardize reporting and to classify reasons for discontinuing home dialysis	✓	✓
Patient-reported experience and outcomes measures	- Selection of kidney-specific versus generic measures - Value of repeated assessments vs survey fatigue - Validation and discrimination of the measures employed - Response bias including disparities among responders versus non-responders⁶³ - Heterogeneity of domains - Measure quantifies a health status that is otherwise difficult to capture - Cultural and health literacy generalizability - Separate tools potentially needed for care-partners	✓	✓
Hospitalization	- Uncertainty regarding whether time in hospital (e.g., length of stay) versus frequency of hospitalization is paramount (e.g., rate) - Capture and reporting of hospitalizations in which a modality change took place, and adjudication of such episodes to the appropriate dialysis modality - Differentiating “good” hospitalizations (transplant, elective procedures) from “avoidable” hospitalizations - Emphasis on readmission versus initial admission	✓	✓
PD infections and peritonitis	- Heterogeneity of data capture - Some subjectivity in the definition of a PD-related infection - Work underway to standardize metrics focusing on episodes per patient-year as defined by the ISPD	✓	
Residual kidney function	- Heterogeneity of causes of residual kidney function loss, with some etiologies potentially avoidable and others nonmodifiable - Variability in assessment with some relying on volume and others on measures of solute clearance - High patient burden with collection, and frequent inaccuracy	✓	✓
Biochemical markers of small solute clearance	- Limited data supporting a specific target threshold for small-molecule clearance - Focus on numbers rather than overall well-being to make treatment decisions - Lack of universal data standards, including determining inputs into formal calculations of dialytic urea removal	✓	✓
Noninfectious PD catheter loss	- Distinguishing between modifiable and non-modifiable causes - Regional factors influence access to advanced surgical techniques (such as laparoscopy) - Work is underway to standardize definitions - Registries often do NOT capture access loss prior to PD commencement, missing a high number of individuals with early mechanical complications; metric may be augmented if attempts were made	✓	
Vascular access infection	- Balancing patient preference versus risk, particularly with buttonhole cannulation - May disincentivize more frequent hemodialysis, as the more an access is used, theoretically the higher the risk of infection - May disincentivize home hemodialysis among those with fears of using arteriovenous access by discouraging use of central venous catheters		✓
Vascular access outcomes	Development and validation of outcomes measures for vascular access (e.g., SONG-HD [Standardizing Outcomes in Nephrology-Hemodialysis]; https://songinitiative.org/projects/song-hd/song-hd-vascular-access)		✓
Adverse procedure-related events	- Difficult to ascertain due to relatively rare events that rely on self-reporting - Dependent on patient self-report, resulting in limited and inconsistent ascertainment	✓	✓

HD, hemodialysis; ISPD, International Society for Peritoneal Dialysis; PD, peritoneal dialysis.




Figure 5 | Enabling dialysis at home.

center-, and policy-level components should be balanced to measure the feasibility and outcomes of home dialysis expansion, keeping the patient's perspective central while integrating facility-level and national-level metrics.

When developing and implementing home dialysis quality measures, potential items to evaluate include the proportion of people that select a modality who ultimately receive that modality, as well as the rate of transfer from the home modality to ICHD. The reasons for discontinuing a modality and whether these reasons are modifiable are important to track. These data need to be conceptualized within the context of conservative care and kidney transplantation utilization, both of which vary widely across jurisdictions, impacting measures of home dialysis utilization as depicted in Figure 3. Additional

metrics and domains are discussed in Table 4. Ideally, any list of measures would be parsimonious, would be updated frequently to maintain relevance and immediacy to clinical care, and would help alleviate rather than reinforce disparities in home dialysis utilization.⁶⁵

CHOOSING HOME DIALYSIS

Given evidence suggesting only small differences in outcomes between home and in-center dialysis, modality choice should be preference-sensitive, informed, and individualized based on perceived quality of life, life goals, and symptom burden. Ideally, individuals, their care-partners, and their healthcare teams will decide together on the most appropriate initial modality, using shared decision-making.⁶⁶ Choices may be




Figure 6 | Evaluation and assessment pathway for home-based dialysis therapies. Based on Blake *et al.*, 2013.⁷² eGFR, estimated glomerular filtration rate.

more widely available in higher-income regions, where KRT options are less likely to be constrained by economic factors.

Clinician bias and approach have a strong influence on patient decision-making.⁶⁷ Incumbent upon clinicians is presentation of both dialysis and dialysis modality as choices, emphasizing that several treatment options exist and that many individuals with kidney failure will require, over time, several different kidney failure treatment modalities. Currently, the number of dedicated educators on dialysis modalities is insufficient, especially those who can provide an unbiased, comprehensive view of the spectrum of kidney failure treatment options, including PD, home HD, in-center hemodialysis, transplant, and nondialysis conservative care.⁶⁸

Patient considerations

Factors that have been associated with lower uptake of home dialysis are male sex, minority ethnicity, older age, greater comorbid burden, late referral to kidney care, lower socioeconomic status, obesity, and close proximity to dialysis centers.^{69,70} Patient subgroups, including indigenous populations, minority ethnicities, certain religious groups, displaced persons, lower socioeconomic groups, and those with language barriers, lower health literacy, or cognitive impairment may have more barriers to engaging in decision-making and/or to being offered alternative modalities. These individuals require responsive strategies. Community and cultural experiences can influence individual choice; individuals may feel shame about being ill or that discussions about illness are taboo.

Pragmatically, multiple resources are needed for successful home dialysis, including a safe and clean environment, access to technology, and in many cases, support from family or community (Figure 5). Those who require physical support in performing dialysis may not have a care-partner or access to home support or paid care. Certain programs may discourage or may not support home dialysis for persons who live alone. Patients and families may be concerned about assuming responsibility for therapy, risk of infections, or a perceived lack of support, or they may believe that home therapy represents suboptimal or substandard care. Individuals may worry about imposing treatment on family/household members, and indeed, patients and their families can become fatigued, especially with long-term home care. Space in the home may be limited for materials and equipment, and some individuals may want to separate their home life from dialysis treatments. Waste management and environmental hygiene can also impact decision-making.

That stated, home dialysis has few absolute contraindications. Unstable or insufficient housing may be a barrier to both home HD and PD. Lack of a viable peritoneum, such as when the peritoneum has been damaged through surgery or inflammation, is an absolute contraindication for PD. Lack of vascular access is an absolute contraindication to home HD. Critically, a contraindication to one home modality, such as no remaining HD vascular access sites, may be a firm

indication for a different home modality, such as PD. Relative contraindications to home dialysis exist on a spectrum (for example, mental health and cognitive impairment disorders) and potentially may be overcome with environmental modifications, technology adaptation, and assistance from care-partners or professionals.

Dialysis at home should not be limited to patients with high levels of activation and involvement in self-care as these can be developed with appropriate education and support.⁷¹ For individuals who are reviewed in chronic kidney disease clinics, recurrent evaluation and iterative education and preparedness planning, governed by principles of shared decision-making, are important (Figure 6).⁷² Emotional preparedness, and therefore support, is as important as educational preparedness and may require input from trained mental health professionals. Informing those who start ICHD urgently that changing modality after clinical improvement is a possibility is important.

PATIENT TRAINING

The association between patient-targeted education interventions and the subsequent choice and receipt of PD is strong.⁷³ Uptake of home HD can be increased through stepwise efforts to support and train individuals to participate in specific tasks related to their HD treatment.^{71,74} Educational strategies and formats for training and evaluation vary,^{73,75,76} and they exist for many aspects of dialysis care,⁷⁷ peer support, and peer education.^{78,79}

Above all, education should be iterative, culturally sensitive, and consistent when provided by different team members. For individuals without predialysis care, education that occurs early in the dialysis tenure is imperative. For those who have unplanned starts, a pathway designed for early education that includes home opportunities should be established in each program. Having a dedicated team for new-start patients after discharge from hospital can facilitate education for individuals who may not have received predialysis education or made their modality decision.^{80,81} Education can be provided in groups or one-to-one with healthcare teams, videos (internet, virtual, or video-based), written materials, and peer support. Using a variety of education methods is important, to accommodate learning styles. Educators must have a clear grasp of both home and in-center modalities. Training for healthcare professionals, critical to successful home dialysis programs, is discussed below. Improving clinician education and providing support to small centers are critical for increasing home dialysis utilization.

Qualitative studies evaluating barriers to home HD uptake indicate that self-cannulation is a significant source of fear and anxiety. Resources are needed to help overcome these fears and instill patient confidence.^{82–84} In some cases, use of a central venous catheter rather than arteriovenous access may be a practical, although controversial, solution. Shared center-based HD care, whereby individuals are provided with support and given the choice to learn and perform tasks relating to their own care, may instill important principles of

Table 5 | Different models of assisted peritoneal dialysis delivery

Country	Healthcare system funded	PD modality supported and visits/day	Comments
France ⁹⁵	Community nurses	Predominantly CAPD 3–4 visits; some APD 2 visits	51% incident patients with assisted PD: 82% nurse assisted and 18% family assisted
Denmark ^{96,97}	Community nurses or nursing home staff	Predominantly APD 2 visits	Assisted program also used to support urgent start of PD
Ontario, Canada ^{98,99}	Community nurses	APD 1–2 visits	Family assistance also required for some tasks; many also have access to integrated geriatric care
British Columbia, Canada ¹⁰⁰	Community non-healthcare professionals with PD training	APD 1 visit	Family assistance also required for some tasks
United Kingdom ⁵⁶	Non-healthcare professionals with PD training	Predominantly APD 1–2 visits, or CAPD supported in some centers	Assistants predominantly from healthcare agency organized by commercial supplier of PD fluid; some units employ own assistants; healthcare system reimburses 1 visit
Brazil ¹⁰¹	Nurse assistant	APD 1–2 visits	Single-center experience; PD funded by renal center, as not reimbursed by public healthcare system
China ^{102,103}	Family, home care assistant, younger PD patients	CAPD	Funded by family/patient; some centers train younger PD patients to assist older ones
Saudi Arabia ¹⁰⁴	Family, home care assistant	CAPD, APD	Funded by family/patient; single-center report

APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; PD, peritoneal dialysis.

self-management, enabling more people to consider home dialysis.⁷¹ This requires that all dialysis nurses and care professionals receive specific training, so that patient education becomes part of the routine delivery of care.

Availability of a range of PD catheter-insertion techniques, including percutaneous and surgical, allows use of the most appropriate approach given the individual patient characteristics. The percutaneous technique utilized by expert operators can often enable PD to be started in a timely manner for suitable individuals, whereas advanced laparoscopic surgical approaches may be preferred in patients with complex intra-abdominal considerations.^{85,86}

Peer support should be facilitated by dialysis programs because it provides vital and unique insights for new patients who are considering home therapies. Dialysis programs can work with local patient kidney organizations; in the United States, the National Kidney Foundation, and in the United Kingdom, the National Kidney Federation have initiated such a program (<https://www.kidney.org.uk/peer-support>).⁷⁹ Webinars or seminars targeted to patients and families can address myths relating to home dialysis and can ease individual concerns by providing open-question periods. Patient and care-partner input into the development of these programs is crucial (including home-dialysis patients and those who did not choose home dialysis). Studies of whether peer support groups increase home dialysis utilization are needed.

Home visits support individual and family confidence in the home. Managing patient expectations and specifying that a change of modalities may be necessary in the future are important. Anxiety is common with early in-home practice, and provision of details regarding support contacts is essential, for reassurance and to enable problem solving. Reassurance should be provided that nursing or medical and technical support will continue when patients are at home.

Although no clear evidence indicates that decision aids impact usage of home dialysis, they can improve patient clarity and autonomy in decision-making and increase perception of control.⁸⁷ Example decision aids are the Yorkshire Dialysis decision aid,⁸⁷ the SHERPA decision aid, the National Patient Decision Aid for Established Renal Failure, the My Kidneys My Choice aid, and the Decision Aid for Renal Therapy.⁸⁸ They should be employed as part of, and not as a replacement for, standard in-person education. A 3-talk model of shared decision-making comprises a series of sessions for dialysis education, exploration of potential benefits and drawbacks for each modality, and a session in which the patient decision is made and evaluated.^{89,90}

Patients report having a positive feeling toward remote consultation and monitoring, but they feel that neither should replace face-to-face clinical contact.^{91–93} Remote monitoring may be embraced by clinicians as a means of assessing whether patients are safely using home dialysis. Despite the

high interest in using remote monitoring, good-quality evidence of effectiveness is needed before its widespread use in home dialysis is implemented.⁹⁴

Assisted home dialysis

Assisted home dialysis refers to the provision of assistance to individuals receiving home dialysis by care-partners (i.e., family or friends), or hired staff (i.e., professionally trained dialysis nurses, personal support workers, community health workers, or other skilled aides) (Table 5^{56,95–104}). Assistance can be nontechnical (for example, carrying dialysate bags into patient rooms), technical (machine setup, dialysis-related operations), clinical (evaluation of exit site, fluid-volume assessment), partial or complete, temporary or permanent, and paid or unpaid.

Family assistance for PD is ubiquitous, as reflected by evidence that the presence of social support is associated with greater uptake of PD.¹⁰⁵ Healthcare-provided assistance is more limited. France has the longest experience of assisted PD, predominantly as assisted continuous ambulatory PD using community nurses.⁹⁵ In the United Kingdom, assisted PD provided by healthcare assistants has been shown to increase the rate of PD initiation, particularly in older patients.¹⁰⁶ Funded assisted PD, however, is not available in the majority of European countries.¹⁰⁷ Data from Canada indicates that nurse-assisted PD is associated with better technique survival, compared with that of family or self-care PD.¹⁰⁸

Unpaid care-partner assistance occurs commonly. The majority of assisted PD in Asia and the Middle East is performed by domestic helpers, often as an additional workload.^{109,110} In Malaysia, full or partial assistance by care-partners is documented in a renal registry, and no community nurse assistance is available. In the US, access to assistance is limited; some individuals have unpaid care-partners or hire private assistants. Notably, a recent feasibility study showed that appropriately trained nonregistered nurse assistants can successfully support patients on PD within the US healthcare system, at least on a temporary basis.¹¹¹

For assisted home dialysis, relative program evaluations are difficult. A recent systematic review and jurisdictional scan evaluating the role of assisted PD across 34 studies, 46,597 patients, and 20 jurisdictions could not demonstrate clear clinical and economic benefits of PD assistance.¹¹² This failure to find benefit was likely due to the heterogeneity of study quality, outcomes, and models and types of assistances. Cost effectiveness and clinical outcomes evaluations of assisted home dialysis can be considered against both center-based dialysis and conservative, non-dialysis care.

Strategies to decrease care burden without substantially increasing costs could include the following: adjusting the prescription for residual kidney function (fewer exchanges per day or incorporating days off dialysis, referred to as incremental dialysis); early and frequent education and

monitoring for burnout; time-limited staff-assisted home dialysis during periods in which home dialysis departure or complication rates are high (e.g., after falls or fractures); public-private partnerships (cost-sharing between government and dialysis organizations); and nominal incentives to care-partners (monetary or otherwise).

Care-partners require specific support; data suggest that their quality of life is poorer than that of the general population.¹¹³ The optimal methods for educating and supporting care-partners of dialysis patients are not clear. Care-partners may benefit from some “time out” or “respite” that is scheduled proactively; this time is an important part of home dialysis programs (provided resources are adequate to support this approach). This respite can be provided as assistance or ICHD for distinct time periods or limited days, such as 1–3 days per week. Routine evaluation for burnout and proactive referrals are essential.

HOME DIALYSIS PROGRAM DEVELOPMENT AND PROVIDER EDUCATION

Home dialysis programs engage multiple stakeholders to serve the local community.¹¹⁴ Although each program is unique, development of a home dialysis program is underpinned by certain key principles, including the following: equity of access; patient, care-partner, and/or other stakeholder involvement; the addressing of population needs within the local healthcare system; clinical leadership; shared decision-making; and a quality-improvement culture.¹¹⁵ Successful PD and home HD access programs are vital parts of all dialysis programs, with home dialysis integrated with existing ICHD and transplantation, such that each modality is viewed as complementary, not competitive. An organized, standardized approach is needed to identify new dialysis starts, assess home dialysis eligibility, and provide modality education and support while enabling individuals to make an informed decision regarding a treatment strategy.¹¹⁶ Complex, multi-system, evidence-based systematic clinic-based interventions (i.e., education, feedback, and audits) have not always demonstrated benefit of increased utilization of home dialysis.¹¹⁷ This finding underscores the importance of stakeholder accountability (i.e., incentives/penalties) and feedback from patients’ care-partners and providers for the success of any intervention. The development and implementation of local quality-improvement initiatives may be more successful for increasing home dialysis utilization than top-down approaches.¹¹⁷

A roadmap for developing home dialysis programs includes local assessment of needs; mentorship/support by local/regional expertise; a realistic plan for growth, underpinned by adequate resources and staff requirements, with competencies, safety training, and retention support; and standardization of processes and procedures (e.g., patient education, access creation, and treatment of common complications). Facility culture is key for maintaining a successful program.¹¹⁸

The most appropriate working arrangements for care teams will be influenced by the patient population and the number of available staff across disciplines. A meta-analysis of 10 studies of PD found a mortality benefit with larger centers,¹¹⁹ although this could be due in part to newer centers having a smaller number of patients. These findings also suggest that smaller centers may need additional support over time.

Training health professionals

All healthcare professionals involved in caring for persons with kidney disease should receive early and comprehensive core training in all KRT options, including home dialysis.¹²⁰ This training should include contact during fellowship training that involves treating patients with home dialysis; such training is important both for building physician confidence in home dialysis care and limiting physician bias regarding home dialysis eligibility among certain individuals or patient groups.¹²¹ Continuous maintenance training is necessary for nephrologists and nurses. Training should be underpinned by a system of competencies and responsibilities that will differ based upon local resources and healthcare systems. The full multidisciplinary team contributing to staff education in home dialysis gives a unified message that builds individual confidence.

Home dialysis experts and educators

Home dialysis specialists have a specific skill set that requires recognition—it includes modality expertise combined with complex case management in the home setting. Rotating/mixing these specialists with other subspecialty experts risks diluting this expertise but may be necessary in smaller or resource-limited settings where individuals have multiple responsibilities. Specific home-dialysis educators and navigation specialists are professionals essential to the increased uptake of home therapies, as they can provide patient education that supports modality choice.

Modality transitions

Modality transitions are common and result from complications such as mechanical problems or infections, changes in social circumstances, or the development of additional comorbid conditions.¹²² They can occur among any of the dialysis modalities, are often complex for centers to manage, and can be distressing and frightening for patients. When possible, transitions should be anticipated and planned for,¹²³ with a focus on improving patient quality of life as well as facilitating access to patient-centered HD regimes (e.g., adjustments to the intensity of HD therapy).^{11,124} Successful transition is underpinned by protocols that require the following: comprehensive patient-centered education; support of a multidisciplinary healthcare team; well-defined care models delivered by dedicated staff skilled in patient training, monitoring, and support; and adequate infrastructure and organization.^{11,77,115,123,125,126} Strategies to increase home-to-home dialysis transitions may need to focus on integrating home dialysis (home HD and PD) care whereby equal

experience and comfort exists across all home dialysis modalities^{127–129}; addressing unique patient barriers to home HD; and promoting technologic advances that simplify performing either PD or home HD.

Insights from the coronavirus disease 2019 (COVID-19) pandemic

The COVID-19 pandemic demonstrated the need to build system resilience for all possible disaster types and dialysis modalities. It illustrated difficulties in surgical dialysis access prioritization, provision supply chain problems, and vulnerability to staffing shortages.¹³⁰ The pandemic also highlighted the benefits of being able to dialyze at home amidst widespread challenges in obtaining and providing healthcare. Indeed, home dialysis can be advantageous in terms of flexibility and safety,¹³¹ but it relies on the availability of supplies and consistent access to electricity and clean water.¹³² Across some jurisdictions, the use of PD increased during the pandemic, but across many regions, training of new patients and reduction in access to PD catheter insertion may have restricted home dialysis growth.^{133,134} Important lessons learned from the pandemic to improve home dialysis care and provision include prioritizing strategies and healthcare policies that maximize successful and timely PD access placement, exploring the role of and improving access to telemedicine, building redundancies in facility staffing and home dialysis training resources, and enhancing support so that patients can continue to receive treatment at home.¹³⁵

CONCLUSION

Our controversies conference reaffirmed the need for advocacy and efforts to ensure equitable access to home dialysis to all individuals in need of KRT globally. Multiple research needs exist, and a systematic prioritization would aid implementation, although this undertaking was outside the scope of this conference. The importance of context, choice, and education in facilitating successful home dialysis is clear. There is no one-size-fits-all model for promoting and delivering home dialysis at any level, from patient to facility to healthcare system. Effective approaches are multipronged, engage multiple stakeholders, and take account of local circumstances. Clinical studies comparing modalities are limited in their generalizability; however, existing evidence suggests in-center dialysis, PD, and home HD are sufficiently similar in clinical outcomes to support personalized and individual choice among these options.

The conference agenda, scope of work, and plenary presentations can be found at <https://kdigo.org/conferences/hd/>.

APPENDIX

Other Conference Participants: Alferso C. Abrahams, Netherlands; Samaya J. Anumudu, USA; Joanne M. Bargman, Canada; Peter G. Blake, Canada; Natalie Borman, UK; Elaine Bowes, UK; James O. Burton, UK; Agnes Caillette-Beaudoin, France; Yeoungjee Cho, Australia; Brett Cullis, South Africa; Yael Einbinder, Israel; Osama El Shamy, USA; Kevin F. Erickson, USA; Ana E. Figueiredo, Brazil; Fred O. Finkelstein, USA; Richard J. Fluck, UK; Jennifer E. Flythe, USA; James Fotheringham, UK; Masafumi Fukagawa, Japan; Eric Goffin, Belgium; Thomas A. Golper, USA; Rafael Gómez, Colombia; Vivekanand Jha, India; David W.

Johnson, Australia; Talermsak Kanjanabuch, Thailand; Yong-Lim Kim, South Korea; Mark Lambie, UK; Edgar V. Lerra, USA; Robert S. Lockridge Jr, USA; Fiona Loud, UK; Ikuto Masakane, Japan; Nicola Matthews, Canada; William S. McKane, UK; David C. Mendelssohn, Canada; Thomas Mettang, Germany; Sandip Mitra, UK; Geraldine Biddle Moore, USA; Thyago Proença de Moraes, Brazil; Rachael L. Morton, Australia; Lily Mushahar, Malaysia; Annie-Claire Nadeau-Fredette, Canada; KS Nayak, India; Joanna L. Neumann, USA; Grace Ngaruiya, Kenya; Ikechi G. Okpechi, South Africa; Robert R. Quinn, Canada; Janani Rangaswami, USA; Yuvaram N.V. Reddy, USA; Brigitte Schiller, USA; Jenny I. Shen, USA; Rukshana Shroff, UK; María Fernanda Slon-Roblero, Spain; Laura Solá, Uruguay; Henning Søndergaard, Denmark; Isaac Teitelbaum, USA; Karthik K. Tennankore, Canada; Floris Vanommeslaeghe, Belgium; Rachael C. Walker, New Zealand; Robert J. Walker, New Zealand; Angela Yee-Moon Wang, Hong Kong; Bradley A. Warady, USA; Suzanne Watnick, USA; Eric D. Weinhandl, USA; Caroline M. Wilkie, USA; and Jennifer Williams, UK.

DISCLOSURE

JP has declared receiving research support from Agency for Healthcare Research and Quality (AHRQ); consultant fees from Amgen, AstraZeneca, Baxter Healthcare, Bayer, GSK, and Otsuka; fees for speakers bureaus from Amgen, Baxter Healthcare, Fresenius Medical Care, Innovative Renal Care, and US Renal Care; research salary support from Arbor Research Collaborative for Health; and travel support from liberDi; he has also served as council member for ISPD and NAC ISPD and ASN Home Dialysis SC Chair. EAB has declared receiving consultant fees from Baxter Healthcare; fees for speakers bureaus from Baxter Healthcare and Vifor; and stock from AWAK and liberDi; she is also the current President of International Society for Peritoneal Dialysis (ISPD). CTC has declared receiving research support from Medtronic; consultant fees from Dialco and Quanta; and serving on the Data Safety Monitoring Board of NightLife trial. SJD has declared receiving research support from National Institute for Health and Care Research (NIHR) and EU Horizon 2020; fees for speakers bureaus from Baxter Healthcare and Fresenius Medical Care; and travel support from Baxter Healthcare. SJD has also declared serving as a medical advisory board member for Ellen; President of EuroPD, Trustee of Kidney Research UK; and Committee Chair of ISPD. RK has declared receiving fees for speakers bureaus from Baxter Healthcare. SK has declared being Director of the Real World Evidence Consortium and Alberta Drug and Therapeutic Evaluation Consortium (Universities of Alberta, Calgary, and Institute of Health Economics). AL has declared serving as Secretary and Executive of ISPD, Chair of ISN Renal Disaster Preparedness Working Group, and Associate Editor of *Nephrology*. DEW has declared being on the Data Safety Monitoring Board of Quanta SC and HOME-BP, and serving as a Kidney Care Partners Representative for ASN and Medical Director of Clinical Research for Dialysis Clinic, Inc. MJ has declared receiving research support from Amgen and AstraZeneca; consultant fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Fresenius Medical Care Asia Pacific, GSK, and Mundipharma; and fees for speakers bureaus from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, and Mundipharma; he is the present Co-Chair of KDIGO. WCW has declared receiving consultant fees from Akebia/Otsuka, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, GSK, Merck, Pharmacosmos, Reata, and Zydus; and he is the present Co-Chair of KDIGO. MEW has declared receiving fees for speakers bureaus from Baxter Healthcare and Fresenius; travel support from Baxter Healthcare; and fees for providing expert advice on product development for Triomed AB Sweden. The other authors declared no competing interests.

ACKNOWLEDGMENTS

The conference was sponsored by KDIGO and was supported in part by unrestricted educational grants from Akebia, AstraZeneca, Baxter, Boehringer Ingelheim, CVS Kidney Care, Fresenius Medical Care, Home Dialyzors United, Lilly, Otsuka, Outset, and US Renal Care. The authors thank Jennifer King, PhD, for assistance with manuscript preparation.

REFERENCES

- Walker RC, Hanson CS, Palmer SC, et al. Patient and caregiver perspectives on home hemodialysis: a systematic review. *Am J Kidney Dis*. 2015;65:451–463.
- Dahlerus C, Quinn M, Messersmith E, et al. Patient perspectives on the choice of dialysis modality: results from the Empowering Patients on

- Choices for Renal Replacement Therapy (EPOCH-RRT) Study. *Am J Kidney Dis*. 2016;68:901–910.
- Chaudhary K, Sangha H, Khanna R. Peritoneal dialysis first: rationale. *Clin J Am Soc Nephrol*. 2011;6:447–456.
- Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. *JAMA*. 2007;298:1291–1299.
- McFarlane PA, Pierratos A, Redelmeier DA. Cost savings of home nocturnal versus conventional in-center hemodialysis. *Kidney Int*. 2002;62:2216–2222.
- Rubin HR, Fink NE, Plantinga LC, et al. Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. *JAMA*. 2004;291:697–703.
- Chuasuwana A, Pooripussarakul S, Thakkinstian A, et al. Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis. *Health Qual Life Outcomes*. 2020;18:191.
- Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis. *J Am Soc Nephrol*. 2012;23:533–544.
- Harris DCH, Davies SJ, Finkelstein FO, et al. Increasing access to integrated ESKD care as part of universal health coverage. *Kidney Int*. 2019;95:S1–S33.
- Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet*. 2015;385:1975–1982.
- Chan CT, Blankestijn PJ, Dember LM, et al. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2019;96:37–47.
- Flythe JE, Chang TI, Gallagher MP, et al. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2020;97:861–876.
- Brown EA, Zhao J, McCullough K, et al. Burden of kidney disease, health-related quality of life, and employment among patients receiving peritoneal dialysis and in-center hemodialysis: findings from the DOPPS Program. *Am J Kidney Dis*. 2021;78:489–500.e1.
- Cho Y, Bello AK, Levin A, et al. Peritoneal dialysis use and practice patterns: an international survey study. *Am J Kidney Dis*. 2021;77:315–325.
- Organisation for Economic Co-operation and Development. OECD health statistics 2022. Accessed February 8, 2023. <https://www.oecd.org/health/health-data.htm>
- Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. *Kidney Int*. 1996;50:235–242.
- Canadian Agency for Drugs and Technologies in Health (CADTH). Dialysis modalities for the treatment of end-stage kidney disease: a health technology assessment—project protocol: CADTH optimal use report. No. 6.2a. Accessed February 8, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK409527/>
- van der Tol A, Lameire N, Morton RL, et al. An international analysis of dialysis services reimbursement. *Clin J Am Soc Nephrol*. 2019;14:84–93.
- Chungsaman P, Kasemsup V. PD first policy: Thailand's response to the challenge of meeting the needs of patients with end-stage renal disease. *Semin Nephrol*. 2017;37:287–295.
- Changsirikulchai S, Sriprach S, Thokanit NS, et al. Survival analysis and associated factors in Thai patients on peritoneal dialysis under the PD-first policy. *Perit Dial Int*. 2018;38:172–178.
- Barraclough KA, Agar JWM. Green nephrology. *Nat Rev Nephrol*. 2020;16:257–268.
- Karopadi AN, Mason G, Rettore E, et al. Cost of peritoneal dialysis and haemodialysis across the world. *Nephrol Dial Transplant*. 2013;28:2553–2569.
- Weinhandl ED, Saffer TL, Aragon M. Hidden costs associated with conversion from peritoneal dialysis to hemodialysis. *Kidney360*. 2022;3:883–890.
- Li PK-T, Lu W, Mak S-K, et al. Peritoneal dialysis first policy in Hong Kong for 35 years: global impact. *Nephrology*. 2022;27:787–794.
- Kanjanabuch T, Takkavatakarn K. Global dialysis perspective: Thailand. *Kidney360*. 2020;1:671–675.
- Vasquez-Jimenez E, Madero M. Global dialysis perspective: Mexico. *Kidney360*. 2020;1:534–537.
- Sanabria M, Devia M, Hernández G, et al. Outcomes of a peritoneal dialysis program in remote communities within Colombia. *Perit Dial Int*. 2015;35:52–61.

28. US Renal Data System. 2022 annual report. End stage renal disease: Chapter 11: International comparisons. Figure 11.16. Distribution of dialysis modality in prevalent patients with ESRD, by country/region. 2020. Accessed February 8, 2023. <https://usrdp-adr.niddk.nih.gov/2022/end-stage-renal-disease/11-international-comparisons>
29. US Renal Data System. 2021 annual report. End stage renal disease: Chapter 11: International comparisons. Figure 11.16. Distribution of dialysis modality in prevalent patients with ESRD, by country/region. 2019. Accessed February 8, 2023. <https://usrdp-adr.niddk.nih.gov/2021/end-stage-renal-disease/11-international-comparisons>
30. Ahmad M, Wallace EL, Jain G. Setting up and expanding a home dialysis program: Is there a recipe for success? *Kidney360*. 2020;1:569–579.
31. Manns B, Agar JWM, Biyani M, et al. Can economic incentives increase the use of home dialysis? *Nephrol Dial Transplant*. 2019;34:731–741.
32. Wallace EL, Allon M. ESKD treatment choices model: Responsible home dialysis growth requires system changes. *Kidney360*. 2020;1:424–427.
33. Han SS, Park JY, Kang S, et al. Dialysis modality and mortality in the elderly: a meta-analysis. *Clin J Am Soc Nephrol*. 2015;10:983–993.
34. Marshall MR, Hawley CM, Kerr PG, et al. Home hemodialysis and mortality risk in Australian and New Zealand populations. *Am J Kidney Dis*. 2011;58:782–793.
35. Mehrotra R, Chiu YW, Kalantar-Zadeh K, et al. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med*. 2011;171:110–118.
36. Liem YS, Wong JB, Hunink MG, et al. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. *Kidney Int*. 2007;71:153–158.
37. Vonesh EF, Snyder JJ, Foley RN, et al. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. *Kidney Int*. 2004;66:2389–2401.
38. Oliver MJ, Al-Jaishi AA, Dixon SN, et al. Hospitalization rates for patients on assisted peritoneal dialysis compared with in-center hemodialysis. *Clin J Am Soc Nephrol*. 2016;11:1606–1614.
39. van de Luijckgaarden MW, Noordzij M, Stel VS, et al. Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. *Nephrol Dial Transplant*. 2011;26:2940–2947.
40. Haapio M, Helve J, Kyllonen L, et al. Modality of chronic renal replacement therapy and survival—a complete cohort from Finland, 2000–2009. *Nephrol Dial Transplant*. 2013;28:3072–3081.
41. McDonald SP, Marshall MR, Johnson DW, et al. Relationship between dialysis modality and mortality. *J Am Soc Nephrol*. 2009;20:155–163.
42. Tanna MM, Vonesh EF, Korbet SM. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. *Am J Kidney Dis*. 2000;36:1175–1182.
43. Trinh E, Chan CT, Perl J. Dialysis modality and survival: done to death. *Semin Dial*. 2018;31:315–324.
44. Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. *Kidney Int*. 2003;64:2222–2228.
45. Fan L, Yang X, Chen Q, et al. Burden of kidney disease among patients with peritoneal dialysis versus conventional in-centre haemodialysis: a randomised, non-inferiority trial. *Perit Dial Int*. 2022;42:246–258.
46. McGregor DO, Buttimore AL, Lynn KL, et al. A comparative study of blood pressure control with short in-center versus long home hemodialysis. *Blood Purif*. 2001;19:293–300.
47. Nitsch D, Steenkamp R, Tomson CR, et al. Outcomes in patients on home haemodialysis in England and Wales, 1997–2005: a comparative cohort analysis. *Nephrol Dial Transplant*. 2011;26:1670–1677.
48. Krahn MD, Bremner KE, de Oliveira C, et al. Home dialysis is associated with lower costs and better survival than other modalities: a population-based study in Ontario, Canada. *Perit Dial Int*. 2019;39:553–561.
49. Weinhandl ED, Liu J, Gilbertson DT, et al. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. *J Am Soc Nephrol*. 2012;23:895–904.
50. Perl J, Na Y, Tennant KK, Chan CT. Temporal trends and factors associated with home hemodialysis technique survival in Canada. *Clin J Am Soc Nephrol*. 2017;12:1248–1258.
51. Pauly RP, Maximova K, Coppens J, et al. Patient and technique survival among a Canadian multicenter nocturnal home hemodialysis cohort. *Clin J Am Soc Nephrol*. 2010;5:1815–1820.
52. Rocco MV, Lockridge RS Jr, Beck GJ, et al. The effects of frequent nocturnal home hemodialysis: The Frequent Hemodialysis Network Nocturnal Trial. *Kidney Int*. 2011;80:1080–1091.
53. Bonenkamp AA, van Eck van der Sluijs A, Hoekstra T, et al. Health-related quality of life in home dialysis patients compared to in-center hemodialysis patients: a systematic review and meta-analysis. *Kidney Med*. 2020;2:139–154.
54. Iyasere O, Brown E, Gordon F, et al. Longitudinal trends in quality of life and physical function in frail older dialysis patients: a comparison of assisted peritoneal dialysis and in-center hemodialysis. *Perit Dial Int*. 2019;39:112–118.
55. Iyasere O, Brown EA, Johansson L, et al. Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis. *Clin Kidney J*. 2019;12:262–268.
56. Iyasere OU, Brown EA, Johansson L, et al. Quality of life and physical function in older patients on dialysis: a comparison of assisted peritoneal dialysis with hemodialysis. *Clin J Am Soc Nephrol*. 2016;11:423–430.
57. Derrett S, Darmody M, Williams S, et al. Older peoples' satisfaction with home-based dialysis. *Nephrology*. 2010;15:464–470.
58. Manera KE, Johnson DW, Craig JC, et al. Establishing a core outcome set for peritoneal dialysis: report of the SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) Consensus Workshop. *Am J Kidney Dis*. 2020;75:404–412.
59. Evangelidis N, Tong A, Manns B, et al. Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey. *Am J Kidney Dis*. 2017;70:464–475.
60. Flanagan EP, Chivate Y, Weiner DE. Home dialysis in the United States: a roadmap for increasing peritoneal dialysis utilization. *Am J Kidney Dis*. 2020;75:413–416.
61. Dalrymple LS, Young EW, Farag YMK, et al. Kidney Health Initiative ESKD Data Standards Project. *Kidney Med*. 2022;4:100495.
62. Rivara MB, Edwards T, Patrick D, et al. Development and content validity of a patient-reported experience measure for home dialysis. *Clin J Am Soc Nephrol*. 2021;16:588–598.
63. Dad T, Tighiouart H, Fenton JJ, et al. Evaluation of non-response to the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey. *BMC Health Serv Res*. 2018;18:790.
64. Weiner D, Watnick S. The ESRD Quality Incentive Program—Can we bridge the chasm? *J Am Soc Nephrol*. 2017;28:1697–1706.
65. Reaves AC, Weiner DE. The ESRD Quality Incentive Program: Everything can be improved. *Am J Kidney Dis*. 2021;78:907–910.
66. de Jong RW, Stel VS, Rahmel A, et al. Patient-reported factors influencing the choice of their kidney replacement treatment modality. *Nephrol Dial Transplant*. 2022;37:477–488.
67. Ladin K, Pandya R, Perrone RD, et al. Characterizing approaches to dialysis decision making with older adults: a qualitative study of nephrologists. *Clin J Am Soc Nephrol*. 2018;13:1188–1196.
68. Koch-Weser S, Porteny T, Rifkin DE, et al. Patient education for kidney failure treatment: a mixed-methods study. *Am J Kidney Dis*. 2021;78:690–699.
69. Ethier I, Cho Y, Hawley C, et al. Effect of patient- and center-level characteristics on uptake of home dialysis in Australia and New Zealand: a multicenter registry analysis. *Nephrol Dial Transplant*. 2020;35:1938–1949.
70. Castledine CI, Gilg JA, Rogers C, et al. Renal centre characteristics and physician practice patterns associated with home dialysis use. *Nephrol Dial Transplant*. 2013;28:2169–2180.
71. Wilkie M, Barnes T. Shared hemodialysis care: increasing patient involvement in center-based dialysis. *Clin J Am Soc Nephrol*. 2019;14:1402–1404.
72. Blake PG, Quinn RR, Oliver MJ. Peritoneal dialysis and the process of modality selection. *Perit Dial Int*. 2013;33:233–241.
73. Devoe DJ, Wong B, James MT, et al. Patient education and peritoneal dialysis modality selection: a systematic review and meta-analysis. *Am J Kidney Dis*. 2016;68:422–433.
74. Fotheringham J, Barnes T, Dunn L, et al. A breakthrough series collaborative to increase patient participation with hemodialysis tasks: a stepped wedge cluster randomised controlled trial. *PLoS One*. 2021;16:e0253966.
75. Figueiredo AE, Bernardini J, Bowes E, et al. A syllabus for teaching peritoneal dialysis to patients and caregivers. *Perit Dial Int*. 2016;36:592–605.

76. Wood E. Patient-to-patient peer support in renal care: what, why and how? *J Renal Nurs.* 2014;6:239–243.
77. Green JA, Boulware LE. Patient education and support during CKD transitions: when the possible becomes probable. *Adv Chronic Kidney Dis.* 2016;23:231–239.
78. Appleby S. Shared care, home haemodialysis and the expert patient. *J Ren Care.* 2013;39(suppl 1):16–21.
79. National Kidney Foundation. NKFpeers. Accessed February 8, 2023. <https://www.kidney.org/peers>
80. Rioux JP, Cheema H, Bargman JM, et al. Effect of an in-hospital chronic kidney disease education program among patients with unplanned urgent-start dialysis. *Clin J Am Soc Nephrol.* 2011;6:799–804.
81. Hanko J, Jastrzebski J, Nieva C, et al. Dedication of a nurse to educating suboptimal haemodialysis starts improved transition to independent modalities of renal replacement therapy. *Nephrol Dial Transplant.* 2010;26:2302–2308.
82. Moore C, Majeed-Ariss R, Jayanti A, et al. How an ordeal becomes the norm: a qualitative exploration of experiences of self-cannulation in male home haemodialysis patients. *Br J Health Psychol.* 2018;23:544–560.
83. Cafazzo JA, Leonard K, Easty AC, et al. Patient-perceived barriers to the adoption of nocturnal home hemodialysis. *Clin J Am Soc Nephrol.* 2009;4:784–789.
84. Pipkin M, Eggers PW, Larive B, et al. Recruitment and training for home hemodialysis: experience and lessons from the Nocturnal Dialysis Trial. *Clin J Am Soc Nephrol.* 2010;5:1614–1620.
85. Crabtree JH, Shrestha BM, Chow KM, et al. Creating and maintaining optimal peritoneal dialysis access in the adult patient: 2019 update. *Perit Dial Int.* 2019;39:414–436.
86. Perl J, Pierratos A, Kandasamy G, et al. Peritoneal dialysis catheter implantation by nephrologists is associated with higher rates of peritoneal dialysis utilization: a population-based study. *Nephrol Dial Transplant.* 2015;30:301–309.
87. Winterbottom AE, Gavaruzzi T, Mooney A, et al. Patient acceptability of the Yorkshire Dialysis Decision Aid (YoDDA) Booklet: a prospective non-randomized comparison study across 6 predialysis services. *Perit Dial Int.* 2016;36:374–381.
88. Ladin K, Tighiouart H, Bronzi O, et al. Effectiveness of an intervention to improve decision making for older patients with advanced chronic kidney disease: a randomized controlled trial. *Ann Intern Med.* 2023;176:29–38.
89. Amir N, McCarthy HJ, Tong A. A working partnership: a review of shared decision-making in nephrology. *Nephrology (Carlton).* 2021;26:851–857.
90. Finderup J, Dam Jensen J, Lomborg K. Evaluation of a shared decision-making intervention for dialysis choice at four Danish hospitals: a qualitative study of patient perspective. *BMJ Open.* 2019;9:e029090.
91. Walker RC, Tong A, Howard K, et al. Patients' and caregivers' expectations and experiences of remote monitoring for peritoneal dialysis: a qualitative interview study. *Perit Dial Int.* 2020;40:540–547.
92. Antoun J, Brown DJ, Jones DJW, et al. Understanding the impact of initial COVID-19 restrictions on physical activity, wellbeing and quality of life in shielding adults with end-stage renal disease in the United Kingdom dialysing at home versus in-centre and their experiences with telemedicine. *Int J Environ Res Public Health.* 2021;18:3144.
93. Ewart C, Baharani J, Wilkie M, Thomas N. Patient perspectives and experiences of remote consultations in people receiving kidney care: a scoping review. *J Ren Care.* 2022;48:143–153.
94. Cartwright EJ, Zs Goh Z, Foo M, et al. eHealth interventions to support patients in delivering and managing peritoneal dialysis at home: a systematic review. *Perit Dial Int.* 2021;41:32–41.
95. Boyer A, Lanot A, Lambie M, et al. Trends in assisted peritoneal dialysis over the last decade: a cohort study from the French Peritoneal Dialysis Registry. *Clin Kidney J.* 2020;13:1003–1011.
96. Bechade C, Llobedez T, Ivarsen P, et al. Assisted peritoneal dialysis for older people with end-stage renal disease: the French and Danish experience. *Perit Dial Int.* 2015;35:663–666.
97. Povlsen JV, Sorensen AB, Ivarsen P. Unplanned start on peritoneal dialysis right after PD catheter implantation for older people with end-stage renal disease. *Perit Dial Int.* 2015;35:622–624.
98. Oliver MJ, Quinn RR, Richardson EP, et al. Home care assistance and the utilization of peritoneal dialysis. *Kidney Int.* 2007;71:673–678.
99. Fonseca-Correa JI, Farragher JF, Tomlinson G, et al. Longitudinal changes in the use of PD assistance for patients maintained on peritoneal dialysis. *Kidney360.* 2021;2:469–476.
100. Bevilacqua MU, Turnbull L, Saunders S, et al. Evaluation of a 12-month pilot of long-term and temporary assisted peritoneal dialysis. *Perit Dial Int.* 2017;37:307–313.
101. Franco MR, Fernandes N, Ribeiro CA, et al. A Brazilian experience in assisted automated peritoneal dialysis: a reliable and effective home care approach. *Perit Dial Int.* 2013;33:252–258.
102. Xu R, Zhuo M, Yang Z, et al. Experiences with assisted peritoneal dialysis in China. *Perit Dial Int.* 2012;32:94–101.
103. Pommer W, Su X, Zhang M, et al. Implementing assisted peritoneal dialysis in renal care: a Chinese-German perspective. *Kidney Blood Press Res.* 2018;43:1646–1654.
104. Al Wakeel JS, Al Ghonaim MA, Aldohayan A, et al. Appraising the outcome and complications of peritoneal dialysis patients in self-care peritoneal dialysis and assisted peritoneal dialysis: a 5-year review of a single Saudi center. *Saudi J Kidney Dis Transpl.* 2018;29:71–80.
105. Oliver MJ, Garg AX, Blake PG, et al. Impact of contraindications, barriers to self-care and support on incident peritoneal dialysis utilization. *Nephrol Dial Transplant.* 2010;25:2737–2744.
106. Boyer A, Solis-Trapala I, Tabinor M, et al. Impact of the implementation of an assisted peritoneal dialysis service on peritoneal dialysis initiation. *Nephrol Dial Transplant.* 2020;35:1595–1601.
107. Brown EA, Ekstrand A, Gallieni M, et al. Availability of assisted peritoneal dialysis in Europe: call for increased and equal access. *Nephrol Dial Transplant.* 2022;37:2080–2089.
108. Maieran SM, Oliver MJ. Health outcomes and cost considerations of assisted peritoneal dialysis: a narrative review. *Blood Purif.* 2021;50:662–666.
109. Ng JK, Chan GC, Chow KM, et al. Helper-assisted continuous ambulatory peritoneal dialysis: Does the choice of helper matter? *Perit Dial Int.* 2020;40:34–40.
110. Bamforth RJ, Beaudry A, Ferguson TW, et al. Costs of assisted home dialysis: a single-payer Canadian model from Manitoba. *Kidney Med.* 2021;3:942–950.e41.
111. Hussein WF, Bennett PN, Anwaar A, et al. Implementation of a staff-assisted peritoneal dialysis program in the United States: a feasibility study. *Clin J Am Soc Nephrol.* 2022;17:703–705.
112. Hofmeister M, Klarenbach S, Soril L, et al. A systematic review and jurisdictional scan of the evidence characterizing and evaluating assisted peritoneal dialysis models. *Clin J Am Soc Nephrol.* 2020;15:511–520.
113. Gilbertson EL, Krishnasamy R, Foote C, et al. Burden of care and quality of life among caregivers for adults receiving maintenance dialysis: a systematic review. *Am J Kidney Dis.* 2019;73:332–343.
114. Silver SA, Harel Z, McQuillan R, et al. How to begin a quality improvement project. *Clin J Am Soc Nephrol.* 2016;11:893–900.
115. Marshall MR, Young BA, Fox SJ, et al. The home hemodialysis hub: physical infrastructure and integrated governance structure. *Hemodial Int.* 2015;19(suppl 1):S8–S22.
116. Quinn RR, Mohamed F, Pauly R, et al. Starting dialysis on time, at home on the right therapy (START): description of an intervention to increase the safe and effective use of peritoneal dialysis. *Can J Kidney Health Dis.* 2021;8:20543581211003764.
117. Manns BJ, Garg AX, Sood MM, et al. Multifaceted intervention to increase the use of home dialysis: a cluster randomized controlled trial. *Clin J Am Soc Nephrol.* 2022;17:535–545.
118. Vest JR, Gamm LD. A critical review of the research literature on Six Sigma, Lean and StuderGroup's Hardwiring Excellence in the United States: the need to demonstrate and communicate the effectiveness of transformation strategies in healthcare. *Implement Sci.* 2009;4:35.
119. Pieper D, Mathes T, Marshall MR. A systematic review of the impact of center volume in dialysis. *BMC Res Notes.* 2015;8:812.
120. Glickman JD, Seshasai RK. Home hemodialysis education during postdoctoral training: challenges and innovations. *Semin Dial.* 2018;31:111–114.
121. Shen JI, Schreiber MJ, Zhao J, et al. Attitudes toward peritoneal dialysis among peritoneal dialysis and hemodialysis medical directors: Are we preaching to the right choir? *Clin J Am Soc Nephrol.* 2019;14:1067–1070.
122. McGill RL, Weiner DE, Ruthazer R, et al. Transfers to hemodialysis among US patients initiating renal replacement therapy with peritoneal dialysis. *Am J Kidney Dis.* 2019;74:620–628.
123. Chan C, Combes G, Davies S, et al. Transition between different renal replacement modalities: gaps in knowledge and care—The Integrated Research Initiative. *Perit Dial Int.* 2019;39:4–12.

124. Robinson BM, Akizawa T, Jager KJ, et al. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. *Lancet*. 2016;388:294–306.
125. Mitra S, Cress C, Goovaerts T. Workforce development and models of care in home dialysis. *Hemodial Int*. 2015;19(suppl 1):543–551.
126. Howard K, McFarlane PA, Marshall MR, et al. Funding and planning: what you need to know for starting or expanding a home hemodialysis program. *Hemodial Int*. 2015;19(suppl 1):523–542.
127. Elbaki MA, Kennedy C, Bargman JM, et al. Home-to-home dialysis transition: a 24-year single-centre experience. *Perit Dial Int*. 2022;42:324–327.
128. Cinà DP, Dacouris N, Kashani M, et al. Use of home hemodialysis after peritoneal dialysis technique failure. *Perit Dial Int*. 2013;33:96–99.
129. Nadeau-Fredette A-C, Bargman JM, Chan CT. Clinical outcome of home hemodialysis in patients with previous peritoneal dialysis exposure: evaluation of the integrated home dialysis model. *Perit Dial Int*. 2015;35:316–323.
130. Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol*. 2020;16:747–764.
131. Hsu CM, Weiner DE, Aweh G, et al. Epidemiology and outcomes of COVID-19 in home dialysis patients compared with in-center dialysis patients. *J Am Soc Nephrol*. 2021;32:1569–1573.
132. Perl J, Thomas D, Tang Y, et al. COVID-19 among adults receiving home versus in-center dialysis. *CJASN*. 2021;16:1410–1412.
133. Poinen K, Er L, Copland MA, et al. Quantifying missed opportunities for recruitment to home dialysis therapies. *Can J Kidney Health Dis*. 2021;8:2054358121993250.
134. Albakr R, Bieber B, Aylward R, et al. An ISN-DOPPS survey of the global impact of the COVID-19 pandemic on peritoneal dialysis services. *Kidney Int Rep*. 2022;7:2196–2206.
135. Oliver MJ, Crabtree JH. Prioritizing peritoneal catheter placement during the COVID-19 pandemic: a perspective of the American Society of Nephrology COVID-19 Home Dialysis Subcommittee. *Clin J Am Soc Nephrol*. 2021;16:1281–1283.